DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
Post Menopausal Osteoporosis
About this trial
This is an interventional treatment trial for Post Menopausal Osteoporosis
Eligibility Criteria
Inclusion Criteria: women 55-80 years of age; post-menopausal for >=5 years; ambulatory. Exclusion Criteria: malignant disease diagnosed within the previous 10 years (except basal cell cancer that has been successfully removed); breast cancer within the previous 20 years; allergy to bisphosphonates; previous treatment with an intravenous bisphosphonate at any time; previous treatment with an oral bisphosphonate within the last 6 months, >1 month of treatment within the last year, or >3 months of treatment within the last 2 years.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
1
2
3
oral placebo daily and IV ibandronate 2 mg q 2 mo
oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo
oral placebo daily and IV ibandronate 3 mg q 3 mo